Rochester, NY 7/14/2009 11:50:31 PM
ARYX - Aryx Keeps Biotech Investors Humble
ARYx Therapeutics, Inc.
ARYx Therapeutics, Inc., ARYX
WhisperFromWallStreet.com offers daily stock alerts to subscribers. Sign up for our free alerts newsletter.
Biotech is a cruel mistress. On a day when I'm beaming over Amgen's success with denosumab, I'm also smarting over Aryx Therapeutics and the disappointing results from a study of its blood-clotting drug. Both stocks are long picks in my Biotech Select model portfolio (defunct but soon to be resurrected, so stay tuned). Amgen is up big Wednesday morning, while Aryx is down bigger. And so it goes with biotech. Aryx reported Tuesday night that its blood-clotting drug tecarfarin failed to demonstrate superiority over the anticoagulant warfarin in a phase II/III study that enrolled about 600 patients with a variety of conditions requiring them to be on chronic blood-thinning therapy.
About WhisperFromWallStreet.com
WhisperfromWallStreet.com is a FREE award winning newsletter that specializes in sending alerts to our subscribers on stocks we think are going to run, why we think so, as well as teaching you how to become a better trader. We scan hundreds of stocks a day to find those that meet our criteria and when we find one, we send you an alert.
Sign up for our FREE alerts newsletter at WhisperfromWallStreet.com
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
